Journal
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
Volume 4, Issue 5, Pages 471-483Publisher
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jnn.2004.078
Keywords
targeting; brain delivery; drug nanocrystals; nanosuspensions; solid lipid nanoparticles; SLN; nanostructured lipid carriers; NLC; large scale production
Ask authors/readers for more resources
Delivery of drugs to the brain is still a major challenge. Successful delivery across the bloodbrain barrier has only been achieved in some cases, e.g., using pro-drugs. The review describes the delivery to the brain using nanoparticulate drug carriers in combination with the novel targeting principle of differential protein adsorption (PathFinder(R) technology). The PathFinder technology exploits proteins in the blood which adsorb onto the surface of intravenously injected carriers for targeting. Apolipoprotein E is the targeting moiety for the delivery of particles to the endothelials of the blood-brain barrier. To reach therapeutic drug level in the brain, nanoparticulate drug carriers with sufficiently high loading capacity are reviewed, including drug nanocrystals (nanosuspensions), lipid drug conjugate (LDC) nanoparticles and lipid nanoparticles (solid lipid nanoparticles-SLN, nanostructured lipid carriers-NLC). The features are described, including regulatory aspects and large scale production.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available